Sean Ainsworth
Sean Ainsworth is CEO and Chairman at Immusoft. He was Executive Director, Clinical Development at Allergan, CEO and Founder at RetroSense Therapeutics, CEO at GeneVivo, LLC, and VP, Corporate Development at Compendia Bioscience. He is a Board Member at Ray Therapeutics, Inc. and Opus Genetics.
Immusoft raises $3M Series B tranche, names Sean Ainsworth CEO as Hurler’s Syndrome therapy nears human trials
Immusoft raised $3 million as the first tranche of its Series B to advance a Hurler’s Syndrome gene therapy into human trials, and appointed veteran biotech executive Sean Ainsworth as CEO while founder Matthew Scholz becomes CTO.
Organizations
See all 9-
Immusoft Executive Officer, Director 2018–present, Chief Executive Officer 2018–present · current
-
Ray Therapeutics, Inc. Board Member 2021–present · current
-
Opus Genetics Board Member 2018–present · current
Education
-
Washington University in St. Louis - Olin Business School MBA, Strategy & Finance · 2000–2002
-
UC San Diego B.S., Microbiology · 1992–1996